Myasthenic crisis

QJM: An International Journal of Medicine

Volumn 102, Issue 2, 2009, Pages 97-107

  Chaudhuri, A ^a,b   Behan, P O ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b QUEEN S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; CHOLINESTERASE INHIBITOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEOSTIGMINE; PENICILLAMINE; PREDNISOLONE; PYRIDOSTIGMINE; RITUXIMAB; STEROID; TACROLIMUS;

ASPIRATION PNEUMONIA; ASSISTED VENTILATION; BOTULISM; BREATHING MUSCLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CORTICOSTEROID INDUCED OSTEOPOROSIS; DIAPHRAGM PARALYSIS; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; EARLY DIAGNOSIS; FACE MUSCLE; GUILLAIN BARRE SYNDROME; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; HYPERSALIVATION; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; MOTOR NEURON DISEASE; MUSCLE ATROPHY; MUSCLE FATIGUE; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; NASOGASTRIC TUBE; NERVE ENDING; NEUROMUSCULAR JUNCTION DISORDER; NEUROMUSCULAR SYNAPSE; NEUROMUSCULAR TRANSMISSION; ONSET AGE; PATHOGENESIS; PLASMAPHERESIS; POLYMYOSITIS; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RACE DIFFERENCE; RECOMMENDED DRUG DOSE; REVIEW; SALIVATION; SEX DIFFERENCE; SIDE EFFECT; SPINAL CORD DISEASE; STOMACH FUNCTION DISORDER; STOMACH SECRETION; SYNAPTIC MEMBRANE; THYMECTOMY; THYMOMA;

EID: 58949101497     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcn152     Document Type: Review

References (40)

1. Robertson DN. Enumerating neurology. Brain 2000; 123:663-4.
2. Vincent A, Letite MI. Neuromuscular junction autoimmune disease: Muscle specific kinase antibodies and treatments for myasthenia gravis. Curr Opin Neurol 2005; 18:519-25.
3. Deymeer F, Gungor-Tuncer O, Yilmaz V, Parman Y, Serdaroglu P, Ozdemir C, et al. Clinical comparison of anti-MuSK-vs anti-ACHR-positive and seronegative myasthenia gravis. Neurology 2007; 68:609-11.
4. Diaz-Manera J, Rojas-Garcia R, Gallardo E, Juarez C, Martinez-Domeno A, Martinez-Ramirez S, et al. Antibodies to AChR, MuSK and VGKC in a patient with myasthenia gravis and Morvan's syndrome. Nature Clin Pract Neurol 2007; 3:405-10.
5. Romi F, Skeie GO, Aarli JA, Gilhaus NE. The severity of myasthenia gravis correlates with serum concentration of titin and ryanodine receptor antibodies. Arch Neurol 2000; 57:1590-2000.
6. Osserman KE. Myasthenia Gravis. New York, Grune & Stratton, 1958.
7. Jaretzki A 3rd, Barohn RJ, Ernstoff RM, Kamanaski HJ, Keesey JC, Penn AS, et al. Myasthenia gravis: Recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 2000; 55:16-23.
8. Juel VC. Myasthenia gravis: Management of myasthenic crisis and perioperative care. Semin Neurol 2004; 24:75-81.
9. Oosterhuis Hans JGH. Myasthenia Gravis. New York, Churchill Livingstone, 1984.
10. Mayer SA. Intensive care of the myasthenic patient. Neurology 1997; 48:S70-5.
11. Lacomis D. Myasthenic crisis. Neurocrit Care 2005; 3:189-94.
12. Thomas CE, Mayer SA, Gungor Y, Swarup R, Webster EA, Chang I, et al Myasthenic crisis: Clinical features, mortality, complications and risk factors for prolonged intubation. Neurology 1997; 48 1253-60.
13. Sellman MS, Mayer RF. Treatment of myasthenic crisis in late life. South Med J 1985; 78:1208-10.
14. Heckmann JM, Owen EP, Little F. Myasthenia gravis in South Africa: racial differences in clinical manifestation. Neuromuscul Disord 2007; 17:929-34.
15. Plauche WC. Myasthenia gravis in mothers and their newborns. Clin Obstet Gynaecol 1991; 34:82-99.
16. Farrugia ME, Robson MD, Clover L, Anslow P, Newson-Davis J, Kennett R, et al. MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis. Brain 2006; 129:1481-92.
17. Deem S. Intensive-care-unit acquired muscle weakness. Respir Care 2006; 51:1042-52.
18. Bae JS, Go SM, Kim BJ. Clinical predictors of steroid-induced exacerbation in myasthenia gravis. J Clin Neurosci 2006; 13 1006-10.
19. Mehta S. Neuromuscular disease causing acute respiratory failure. Respir Care 2006; 51:1016-21.
20. Agarwal R, Reddy C, Gupta D. Noninvasive ventilation in acute neuromuscular respiratory failure due to myasthenic crisis: Case report and review of literature. Emerg Med J 2006; 23:6-7.
21. Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Ann Neurol 1997; 41:789-96.
22. Berrouschot J, Baumann I, Kalichewski P, Sterker M, Schneider D. Therapy of myasthenic crisis. Crit Care Med 1997; 25:1228-35.
23. Murthy JMK, Meena AK, Chowdary G VS, Naryanan Jaishree T. Myasthenic crisis: Clinical features, complications and mortality. Neurol India 2005; 53:37-40.
24. Quereshi AI, Choudhry MA, Akbar MS, Mohammad Y, Chua HC, Yahia AM, et al. Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis. Neurology 1999; 52:629-32.
25. Gajdos P, Tranchant C, Clair B, Bolgert F, Eymard B, Stojkovic T, et al. Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: A randomized double-blind clinical trial. Arch Neurol 2005; 62:1689-93.
26. Trikha I, Singh S, Goyal V, Shukla G, Bhasin R, Behari M. Comparative efficacy of low dose daily, versus alternate day plasma exchange in severe myasthenia gravis: A randomised trial. J Neurol Sci 2007; 254:989-95.
27. Yeh JH, Chen WH, Chiu HC, Bai CH. MuSK antibody clearance during serial sessions of plasmapheresis for myasthenia gravis. J Neurol Sci 2007; 263:191-3.
28. Comerci G, Buffon A, Biondi-Zoccai GG, Ramazzotti V, Romagnoli E, Savino M, et al. Coronary vasospasm secondary to hypercholinergic crisis: an iatrogenic cause of acute myocardial infarction in myasthenia gravis. Int J Cardiol 2005; 103:335-7.
29. Ishizeki J, Nishikawa K, Kunimoto F, Goto F. Post-operative myasthenic crisis successfully treated with immunoadsorption therapy. J Anesth 2005; 19:320-2.
30. Gronseth GS, Barohn RJ. Practice parameter: Thymectomy for autoimmune myasthenia gravis. An evidence based review. Neurology 2000; 55 7-15.
31. Nagaysu T, Yamayoshi T, Matsumoto K, Ide N, Hashizume S, Nomura M, et al. Beneficial effects of plasmapheresis before thymectomy on the outcome of myasthenia gravis. Jpn J Thorac Cardiovasc Surg 2005; 53:2-7.
32. Sharger JB, Nathan D, Brinster CJ, Yousuf O, Spence A, Chen Z, et al Outcome after 151 extended transcervical thymectomies for myasthenia gravis. Ann Thorc Surg 2006; 82:1863-9.
33. Watanabe A, Watanabe T, Obama T, Mawatari T, Ohsawa H, Ichimiya Y, et al. Prognostic factors for myasthenic crisis after transsternal thymectomy in patients with myasthenia gravis. J Thorac Cardiovasc Surg 2004; 127:868-76.
34. Toker A, Tanju S, Sungur Z, Parman Y, Senturk M, Sardaroglu P, et al Videothoracoscopic thymectomy for nonthymomatous myasthenia gravis: results of 90 patients. Surg Endosc 2008; 22:912-16.
35. Thymectomy trial in non-thymomatous myasthenia gravis patients receiving prednisone therapy (ClinicalTrials.gov Identifier NCT00294568).
36. Soleimani A, Moayyeri A, Akhondzadeh Sadatsafavi M, Shaimani HT, Soltanzadeh A. Frequency of myasthenic crisis in relation to thymectomy in generalized myasthenia gravis: A 17 year experience. BMC Neurol 2004; 4:12 doi:10.1186/1471-2377.
37. Rabinstein AA, Mueller-Kroast N. Risk of extubation failure in patients with myasthenic crisis. Neurocrit Care 2005; 3:213-5.
38. Skeie GO, Apostolski S, Evoli A, Gilhus NE, Hart IA, Harms L, et al Guidelines for the treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 2006; 13:691-99.
39. Hart IK, Sathasivam S, Sharshar T. Immunosuppressive agents for myasthenia gravis. Cochrane Database Syst Rev 2007;CD005224.
40. Fregonezi GA, Resqueti VR, Guell R, Pradas J, Casan P. Effects of a 8-week, interval based inspiratory muscle training and breathing retraining in patients with generalized myasthenia gravis. Chest 2005; 128:1524-30.